Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in COPD Patients
NCT00581945Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Primary completion
- May 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Canakinumab with Placebo (2 arms). Primary endpoints: Forced Expiratory Volume in 1 Second at 45 weeks, Forced Expiratory Volume in 1 Second Percent Predicted at 45 weeks and 3 more. Started Jan 2007; status: completed.
02
Drugs
canakinumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00581945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581945.